Gamma’s China grant
This article was originally published in The Tan Sheet
Executive SummaryGamma Pharmaceuticals announces the Western United States Agricultural Trade Association approved the Las Vegas-based firm for up to $300,000 in annual reimbursement for eligible marketing and promotional activities in China. The WUSATA Branded Program is a marketing expense reimbursement program that supports the promotion of U.S. brand name products in foreign markets. On May 15, Gamma commenced shipment of 8 tons of its products including Brilliant Choice Gelibites nutritional supplements. The firm says the reimbursement will contribute to making Gamma's brands household names in China...
You may also be interested in...
Submission surge in late 2019 means a spike in late summer 2020 user fee goals, including 16 novel agents in August alone.
Keeping Track: Approvals For Tazverik And Tepezza, Priority Reviews For Belantamab Mafodotin And Lynparza
The latest drug development news and highlights from our US FDA Performance Tracker.
Accelerated approval in epithelial sarcoma may de-risk the firm’s goals for approval of Tazverik in follicular lymphoma and other larger indications.